Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.55 |
| ▸ | JAK3 | P52333 | 17/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898971 | 0.90 | JAK2 (0.57) | JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL12898884 | 0.87 | JAK2 (0.56) | JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL12898775 | 0.87 | JAK2 (0.61) | JAK2JAK3MKNK2 | |
| SCHEMBL1265665 | 0.87 | JAK2 (0.71) | JAK2JAK3MKNK2 | |
| SCHEMBL12899074 | 0.86 | JAK2 (0.57) | JAK2JAK3MKNK1MKNK2USP1 | |
| SCHEMBL12899058 | 0.85 | JAK2 (0.52) | JAK2JAK3GABRA1GABRA5 | |
| SCHEMBL1264838 | 0.85 | JAK2 (0.54) | JAK2JAK3GABRA1GABRA5 | |
| SCHEMBL12899116 | 0.84 | GABRA1 (0.41) | JAK2JAK3GABRA1GABRA5MKNK1 | |
| SCHEMBL12899059 | 0.83 | JAK2 (0.54) | JAK2JAK3MKNK1MKNK2 | |
| SCHEMBL12898922 | 0.82 | MKNK1 (0.54) | JAK2JAK3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | JAK2 2995/4885JAK3 1092/4885GABRA1 2887/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | JAK2 2995/4885JAK3 1092/4885GABRA1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.